AGP Guinée/Championnat ligue1 : Le Horoya respire devant la SAG, le Fello Star renoue avec la victoire face aux Eléphants de Coléah et l’AS Kaloum battue par l’ASFAG AGP Kindia-Société : Un mort et plus de 600 millions GNF emportés dans conflit domanial à Friguiagbé AGP Kérouané-Education : Le district de Gboodou doté d’une école primaire moderne AGP Guinée-Accident de la circulation : Une cause de mortalité non négligeable ! GNA Assin North and Adansi South DISECs move to maintain peace GNA Ghana Mission in Washington, others donate $59,850 to COVID-19 Fund GNA Orange Support Centre will address SGBV issues in Ghana – UNFPA APS LE JARAAF S’ENGAGE À PAYER LA CAUTION POUR LAMINE DIACK ‘’D’ICI UNE QUINZAINE DE JOURS’’ (PRÉSIDENT) AGP Boké-Ramadan: La Fondation AMA offre des vivres à la population de la Commune Urbaine ANP La Ville de Niamey baptise deux places publiques des noms de Mounkaila Sakoira et Cheick Chaibou Ali

British health secretary: mRNA vaccines to be altered for new strains

  3 Février      12        Santé (9935),


London, Feb 3, (dpa/GNA) – Scientists are looking at how they can change certain vaccines so they can protect people against new mutations of Covid-19, Britain’s health minister said on Wednesday.
Health Secretary Matt Hancock said the aim was to have another vaccine to protect people from new strains of the virus, such as the variant linked to South Africa, which some Britons have been diagnosed with despite not having recently travelled to the country.
His comments followed a Cambridge University study published on Tuesday which has not yet been peer-reviewed, which said the Pfizer/BioNTech vaccine was « likely to be less effective » against the South African variant but was effective against the British variant.
“What we’re aiming to do is amend the vaccine so that there will, in future, be a vaccine that targets this specific mutation and other mutations that scientists advise, but that is a medium term [plan],” Hancock told the BBC broadcaster.
A ministry spokesperson told dpa this would apply to the mRNA vaccines – Pfizer/BioNTech and Moderna – as well as the one made by AstraZeneca/Oxford.
Last week, Moderna announced it was working on a new booster vaccine to address the South African variant.
Two days later, Pfizer announced both it and BioNTech were “prepared to respond” by creating another Covid-19 vaccine if a variant of the virus proved immune to its vaccine.
In the same statement, Pfizer stated it also found protection was lower against the South African variant with its vaccine, however it added it was a « small difference » which is « unlikely to lead to a significant reduction in the effectiveness of the vaccine. »

Dans la même catégorie